Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phosphoproteomics of BYL719 (alpelisib)-Resistant T47D Human Breast Cancer Cell Line

ABSTRACT: The PI3Kalpha-specific inhibitor Alpelisib (BYL719) has been approved for the treatment of metastatic ER+/HER2- breast cancer patients in combination with Fulvestrant. After initial response, patients develop drug resistance and disease relapses. In order to identify signalling pathways contributing to the acquired resistance to BYL719 in breast cancer, we generated BYL719-resistant T47D cells and used them together with the parental cells to perform label-free quantitative phosphoproteomics.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Cell Culture

DISEASE(S): Breast Cancer

SUBMITTER: Kelvin Yip

LAB HEAD: Antonella Papa

PROVIDER: PXD033956 | Pride | 2023-12-05

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer.

Yip Hon Yan Kelvin HYK Shin Sung-Young SY Chee Annabel A Ang Ching-Seng CS Rossello Fernando J FJ Wong Lee Hwa LH Nguyen Lan K LK Papa Antonella A

NPJ precision oncology 20240126 1

Utility of PI3Kα inhibitors like BYL719 is limited by the acquisition of genetic and non-genetic mechanisms of resistance which cause disease recurrence. Several combination therapies based on PI3K inhibition have been proposed, but a way to systematically prioritize them for breast cancer treatment is still missing. By integrating published and in-house studies, we have developed in silico models that quantitatively capture dynamics of PI3K signaling at the network-level under a BYL719-sensitiv ...[more]

PMID: 38273040

Similar Datasets

Identification of AGR2 interacting proteins in T47D cells using label-free quantification

Project description:LC-MS/MS analysis with label-free quantification to identify proteins interacting with AGR2 protein in T47D breast cancer cells

2022-01-03 | PXD012690 | Pride

Mitochondrial COA7 is a heme-binding protein with disulfide reductase activity, which is involved in the early stages of complex IV assembly

Project description:Cytochrome c oxidase assembly factor 7 (COA7) is a metazoan-specific assembly factor, critical for the biogenesis of mitochondrial complex IV (cytochrome c oxidase). Although mutations in COA7 have been linked to complex IV assembly defects and neurological conditions such as peripheral neuropathy, ataxia and leukoencephalopathy, the precise role COA7 plays in the biogenesis of complex IV is not known. Here we show that the absence of COA7 leads to arrest of the complex IV assembly pathway after the initial step where the COX1 module is built, progression from which requires the incorporation of copper, through the biogenesis of the CuA site. The crystal structure of COA7, determined to 2.4 Å resolution, reveals a ‘banana-shaped’ molecule composed of five helix-turn-helix repeats, tethered by disulfide bonds. We find that in solution, purified COA7 binds heme with micromolar affinity, through axial ligation to the central iron atom by histidine and methionine residues. COA7 interacts transiently with the copper metallochaperones SCO1 and SCO2 that function in copper delivery to COX2 and catalyzes the reduction of disulfide bonds within these proteins, which constitute the protein copper binding sites. We therefore propose that COA7 is a heme-binding disulfide reductase that acts in the biogenesis of the CuA site, that underpins complex IV assembly.

2022-03-23 | PXD031589 | Pride

Genome-Wide Progesterone Receptor Binding: Cell Type-Specific and Shared Mechanisms in Uterine Fibroids and Breast Cancer (ChIP-Seq)

Project description:Analysis of genes regulated by RU486 (an progesterone antagonist) in human breast cancer T47D cells and human uterine leiomyoma smooth muscle cells. The hypothesis is that RU486 inhibits tumor growth by inactivating the transcription of multiple genes which trigger critical signaling pathways to induce tumorigenesis in both breast caner and uterine leomyoma. Tissue-specific and common patterns of gene regulation may determine the therapeutic effects of antiprogestins in uterine leiomyoma and breast cancer. We applied ChIP-seq to identify PR-interaction sites in T47D breast cancer cells and primary uterine leiomyoma cells treated with RU486.

2012-09-11 | E-GEOD-40724 | biostudies-arrayexpress

RIME against TRPS1 in breast cancer cell lines

Project description:Identification of TRPS1 interactors in MCF7, T47D and ZR75-1 breast cancer cell lines.

2018-06-12 | PXD009863 | Pride

Support of a bi-faceted role of ERM-NM-2 in ERM-NM-1-positive breast cancer cells.

Project description:Comparison of the basal and estrogen-induced effects on genome-wide transcription in ERM-NM-1-positive breast cancer cell lines T47D and MCF7 after lentiviral transduction with ERM-NM-2. Comparison of ERM-NM-2-transduced T47D and MCF7 cells versus respective control-transduced cells, in the presence of vehicle or estrogen. Each comparison in technical and biological duplicate.

2013-11-21 | E-GEOD-45047 | biostudies-arrayexpress

Gene expression of T47D-MTVL human breast cancer cells growing in normal conditions

Project description:Basal gene expression of T47D-MTVL human breast cancer cells growing in normal conditions Breast cancer cells T47D-MTVL cells were grown in rich media and total RNA was extracted to monitor basal gene expression

2014-02-04 | E-GEOD-49236 | biostudies-arrayexpress

Temporal dynamic reorganization of 3D chromatin in hormone-induced breast cancer and endocrine resistance [T47D]

Project description:To establish a data-driven learning model of the temporal dynamics and 3D chromatin reorganization, we conducted tethered chromatin conformation (TCC) sequencing to examine 3D structure dynamics in estradiol (E2)-induced breast cancer T47D cells and Tamoxifen resistant breast cancer T47D cells.

2019-04-09 | GSE119890 | GEO

Transcription profiling of breast cancer cells with TET-OFF regulated ERb expression treated with estradiol or ICI, an estrogen receptor antagonist

Project description:Assess the full impact of estrogen receptor beta on transcription by a full transcriptome analysis of ERa and ERb-mediated gene regulation in T47D breast cancer cell line with TET-OFF regulated ERb expression.

2007-12-17 | E-MEXP-969 | biostudies-arrayexpress

T47D cell line transfected with various ESR1 fusion genes (or with estrogen treatment), vs. YFP transfection alone

Project description:Gene expression profiling of the downstream transcriptional changes induced by ESR1 fusion genes observed in human breast tumors resistant to hormone therapy Experimental T47D cells stably expressing ESR1 fusion genes (or T47D cells treated with estradiol) vs. T47D cells expressing YFP

2015-06-12 | E-GEOD-69774 | biostudies-arrayexpress

Inclusion bodies formed by polyglutamine and poly(glycine-alanine) are enriched with distinct proteomes but converge in proteins that are risk factors for disease and involved in protein degradation

Project description:Poly(glycine-alanine) (polyGA) is one of the dipolypeptides expressed in Motor Neuron Disease caused by C9ORF72 mutations and accumulates as inclusion bodies in the brain of patients. Superficially these inclusions are similar to those formed by polyglutamine (polyQ) in Huntington’s disease and both have been reported to form an amyloid-like structure suggesting they might aggregate via similar mechanisms to confer cellular dysfunction similarly. Here we investigated which endogenous proteins were enriched in these inclusions and whether aggregation-prone lengths of polyQ (Q97), in context of Huntingtin exon 1, shared similar patterns to aggregation-prone lengths of polyGA (101GA). When co-expressed in the same cell, polyGA101 and HttQ97 inclusions adopted distinct phases with no overlap suggesting different endogenous proteins would be enriched. Proteomic analyses indeed yielded distinct sets of endogenous proteins recruited into the inclusion types. The proteosome, microtubules, Tric chaperones, and translational machinery were enriched in polyGA aggregates, whereas Dnaj chaperones, nuclear envelope and RNA splicing proteins were enriched in polyQ aggregates. Both structures revealed a synergy of degradation machinery including proteins in the polyQ aggregates that are risk factors for other neurodegenerative diseases involving protein aggregation when mutated, which suggests a convergence point in the pathomechanisms of these diseases.

2020-08-18 | PXD018505 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data